We are live on ! Find out more
BHVN

Biohaven Pharmaceutical Holding Company Ltd.
BHVN

Delisted

BHVN was delisted on the 3rd of October, 2022.

Back to rankings

2 hedge funds and large institutions have $20M invested in Biohaven Pharmaceutical Holding Company Ltd. in 2025 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 2 → 2 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

30% less capital invested

Capital invested by funds: $28.7M → $20M (-$8.68M)

Holders
2
Holders Change
–
Holders Change %
0%
% of All Funds
0.03%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
1
Increased
1
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
KCM
Knoll Capital Management
Florida
+$1.69M
2
FIA
FNY Investment Advisers
New York
+$19K

Top Sellers

Rank Fund Capital Flow
1
BC
Birchview Capital
Vermont
-$275K
Name Holding Trade Value Shares
Change 		Change in
Stake
KCM
1
Knoll Capital Management
Florida
$20M +$1.69M +70,457 +9%
FIA
2
FNY Investment Advisers
New York
$19K +$19K +800 New
BC
3
Birchview Capital
Vermont
– -$275K -7,365 Closed

BHVN Hedge Fund Activity: Q1 2025 in Review

2 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q1 2025, worth a combined $20M — down 30% from $28.7M a quarter earlier.

Fund positioning in BHVN was balanced in Q1 2025: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 0 trimmed.

The largest buyer was Knoll Capital Management, adding an estimated $1.69M. The largest seller was Birchview Capital, exiting entirely with an estimated $275K sold.

  • 2 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q1 2025, unchanged from Q4 2024.
  • Funds reported $20M of Biohaven Pharmaceutical Holding Company Ltd. stock for Q1 2025, down 30% quarter-over-quarter.
  • 1 fund opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q1 2025 and 1 closed out, a net change of 0 holders.
  • The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q1 2025 was Knoll Capital Management, an estimated $1.69M added.
  • The largest Biohaven Pharmaceutical Holding Company Ltd. seller in Q1 2025 was Birchview Capital, an estimated $275K sold.

Based on aggregated 13F filings for Q1 2025.